Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial

Authors: Jörge E. Cortes, Alexander E. Perl, Hartmut Döhner, Hagop M. Kantarjian, Giovanni Martinelli, Tibor Kovacsovics, Philippe Rousselot, Björn Steffen, Hervé Dombret, Elihu H. Estey, Stephen A. Strickland, Jessica K. Altman, Claudia D. Baldus, Alan K. Burnett, Alwin Krämer, Nigel H. Russell, Neil P. Shah, Catherine C. Smith, Eunice S. Wang, Norbert Ifrah, Guy Gammon, Denise Trone, Deborah Lazzaretto, Mark J. Levis - The Lancet 2018 cited by 264